NASDAQ:APTO - Aptose Biosciences Stock Price, Forecast & News

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. View Aptose Biosciences' Earnings History.

Aptose Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Aptose Biosciences.

6 brokers have issued 1 year price objectives for Aptose Biosciences' shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Aptose Biosciences' stock price to reach $6.80 in the next year. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for Aptose Biosciences.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptose Biosciences.

Media coverage about APTO stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aptose Biosciences earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Aptose Biosciences.

Aptose Biosciences saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 310,000 shares, a decrease of 32.2% from the December 15th total of 457,200 shares. Based on an average daily trading volume, of 1,000,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.5% of the shares of the company are short sold. View Aptose Biosciences' Current Options Chain.

Some companies that are related to Aptose Biosciences include Editas Medicine (EDIT), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Alector (ALEC), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO), Mesoblast (MESO), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), AVITA MED LTD/S (RCEL) and Atara Biotherapeutics (ATRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Canopy Growth (CGC), Micron Technology (MU), CymaBay Therapeutics (CBAY), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

Aptose Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sanders Morris Harris LLC (0.32%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View Institutional Ownership Trends for Aptose Biosciences.

APTO stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for Aptose Biosciences.

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APTO stock can currently be purchased for approximately $5.88.

Aptose Biosciences has a market capitalization of $421.07 million. The biotechnology company earns $-28,870,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. View Additional Information About Aptose Biosciences.

The official website for Aptose Biosciences is http://www.aptose.com/.

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]